Use of Hydrocortisone and 9-AlphaFluorohydrocortisone Derivatives

Lubowe, I I

doi:10.1001/archderm.1955.03730320066010

Cited by 5 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since their introduction over 50 years ago, topical and systemic corticosteroids have been consistently used as anti-pruritic agents [8]. Malignant and activated T cells are particularly sensitive to cortisone-mediated pro-apoptotic and antiproliferative effects, and thus corticosteroids are commonly used as adjuvant therapy in localized and systemic CTCL [9].…”

Section: Resultsmentioning

confidence: 99%

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Cedeno-Laurent

Singer

Wysocka

et al. 2015

Clinical Immunology

View full text Add to dashboard Cite

Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis of pruritus in atopic dermatitis and CTCL. Here we provide both in vivo and in vitro evidence suggesting that histone deacetylase (HDAC) inhibitors may mitigate itch through lowering of levels of IL-31-expressing T cells. Furthermore, we demonstrate that chemokine receptor type-4 (CCR4)-bearing T cells are a main source of IL-31 in CTCL, and that neutralizing the IL-31 pathway through targeting of the CCR4-expressing T cells may represent a promising therapeutic strategy for symptomatic relief in CTCL.

show abstract

Section: Resultsmentioning

confidence: 99%

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Cedeno-Laurent

Singer

Wysocka

et al. 2015

Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…9a-Fluorohydrocortisone.-The substitution of fluorine for hydrogen in the 9a-position of hydrocortisone increased the oral potency eight-to tenfold with respect to such parameters as eosinopenic and hyperglycemic potencies and ASTH-suppressing, nitrogen-wasting, and antiinflammatory activities (36,133,134). The topical anti-inflammatory action was increased also by a factor of 10 on the basis of studies by Witten (135), Robinson (136), and Lubowe (137), showing that 0.1% and 0.25% concentrations of 9a-fluorohydrocortisone 2 1-acetate were, in the majority of paired comparisons, equivalent in activity to 1.0% and 2.5y0 concentrations of hydrocortisone or hydrocortisone 2 1-acetate, respectively. None of these investigators observed any untoward systemic symptoms when the topical preparations were applied from two to four times daily for periods ranging from a few weeks to several months.…”

Section: Clinical Efficacy Studiesmentioning

confidence: 99%